WSJ BLOG/Health: A.M. Vitals: Data For J&J's Zytiga Supports Wider Use

Date : 03/09/2012 @ 10:10AM
Source : Dow Jones News
Stock : Boston Scientific Corp. (BSX)
Quote : 27.365  -0.215 (-0.78%) @ 2:24PM

WSJ BLOG/Health: A.M. Vitals: Data For J&J's Zytiga Supports Wider Use

Boston Scientific (NYSE:BSX)
Historical Stock Chart

5 Years : From Jul 2012 to Jul 2017

Click Here for more Boston Scientific Charts.

(This story has been posted on The Wall Street Journal Online's Health Blog at http://blogs.wsj.com/health.)

By Mark Long

Here's what's making health news this morning:

J&J Study May Support Wider Use of Cancer Drug (WSJ): A clinical trial of Johnson & Johnson's new drug Zytiga, already approved for late-stage prostate-cancer patients who have previously used chemotherapy, finds the drug also improved survival in men who hadn't undergone chemo.

White House Works to Shape Debate Over Health Law (New York Times): The White House is seizing on an upcoming Supreme Court case on the constitutionality of President Obama's health-care overhaul law to attempt to drum up public support for the benefits provided by the law.

Women Who Drink Moderately Have Lower Stroke Risk (NPR's Shots blog): A study published in Stroke suggests that women who drink one serving of alcohol per day had lower stroke rates than their non-drinking counterparts, possibly, in part, by reducing blood clots.

FDA Rejects AstraZeneca Move On Generic Seroquel Labeling (Dow Jones Newswires): The FDA has rejected a Citizen Petition from the drug company to hold off approving generic versions of the antipsychotic unless they carried the same label warnings as are currently on the brand-name.

Boston Scientific to Buy Cameron Health (WSJ): The device maker said it will pay $150 million up front for closely held Cameron, with additional payments possible hinging on FDA approval and meeting sales goals for Cameron's subcutaneous implantable defibrillator.

LSD Helps to Treat Alcoholism (Nature News): A review of previously published research that appears in the Journal of Psychopharmacology suggests the hallucinogen provides benefits lasting three to six months.

Forget The Robots: Venture Capitalists Change Their Health Care Investments (KQED/NPR/Kaiser Health News): Investors are turning from biotech and medical devices and are instead looking at companies that help providers, patients and payers address changes brought by the health-care overhaul law.

Stem Cells Beat Kidney Rejection (BBC): An eight-patient study published in Science Translational Medicine reports that most of the stem-cell recipients didn't need to take drugs to prevent the organ's rejection by the body.

Image source: iStockphoto

 
 -For continuously updated news from The Wall Street Journal, see WSJ.com at http://wsj.com. 
 

Latest BSX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.